This short study evaluated genome-wide DNA methylation profiles and MGMT promoter methylation in archival diffuse gliomas using MethylDetect MS-HRM technology alongside microarrays.
-
Background: This study evaluated genome-wide DNA methylation profiles and immunohistochemical analysis in archival diffuse gliomas, including glioblastomas. To assess MGMT promoter methylation status across frozen and FFPE tissue samples, Methylation-Sensitive High-Resolution Melting (MS-HRM) technology from MethylDetect ApS was utilized alongside Infinium Methylation-EPIC microarrays.
-
Key Finding: The MGMT promoter methylation assessment demonstrated consistent and reliable results between microarray analysis and MethylDetect MS-HRM testing. Furthermore, no differences were found between the usefulness of freshly frozen (FF) and formalin-fixed paraffin-embedded (FFPE) material for methylation profiling.
-
Conclusion: The findings highlight that targeted methods like MS-HRM provide robust and consistent methylation assessment capabilities, supporting reliable molecular characterization and classification in glioma research applications.
-
Original Article & Authors: Published in Folia Neuropathologica (2024). Authored by Olga Taryma-Leśniak, Kamil Buczkowski, Tomasz Klepinowski, Maciej Jankowski, Szymon Retfiński, Bartłomiej Sagan, Leszek Sagan, Ewa Szutowicz, Kacper Winiarski, Marta Masztalewicz, Przemysław Nowacki, Marta Sobalska-Kwapis, Dominik Strapagiel, Wojciech Kloc, Beata Lipska-Ziętkiewicz, Ewa Iżycka-Świeszewska, and Tomasz K. Wojdacz. Research institutions include the Independent Clinical Epigenetics Laboratory at Pomeranian Medical University in Szczecin, Medical University of Gdansk, University of Lodz, and Copernicus Hospital.
👉 Explore the EpiMelt MGMT Human Methylation Detection Assay Kit
Read the full publication, see the link below ↓
